Aequus appoints Ann Fehr as Chief Financial Officer

Jul 22, 2016

VANCOUVER, BC July 22, 2016 - Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) today announced Ann Fehr is joining the growing specialty pharmaceutical company as its new Chief Financial Officer (CFO) effective July 22, 2016. Ms. Fehr brings to Aequus over 20 years of management experience in corporate finance, treasury, financial planning and analysis, tax, and risk management in a number of rapidly growing entrepreneurial companies.

“We are very fortunate to have Ann join Aequus. Ann’s depth of experience in senior financial positions with high growth companies is ideal for Aequus as we continue to expand our commercial efforts in Canada and advance our development programs,” said Doug Janzen, Chairman and CEO of Aequus. “Over the past year, we have evolved into a revenue-generating entity and have expanded our internal team through the acquisition of TeOra Health to foster this growth strategy. Ann’s diverse background and expertise will further enhance Aequus’ current management team as we continue to build value for our shareholders.”

Ms. Fehr is the Principal at Fehr & Associates, and has held a number of senior level positions including having served as CFO of Carrus Capital Corporation (formerly BioWest Therapeutic Inc.), Global Minerals Ltd., and other companies listed on the TSX. During the course of her management and consulting career, Ms. Fehr has led a number of companies through significant change and corporate milestones such as public listing applications, mergers and acquisitions, as well as strategic planning and execution. Ms. Fehr is also an active volunteer in the community. Since 2013, she has been Treasurer and a Director for the Boys and Girls Clubs of South Coast BC.

“I can’t imagine a more exciting time to join Aequus,” Ms. Fehr said. “I look forward to working with the Aequus team to ensure we are financially well positioned for success.”

The Company also announces that Ms. Christina Yip will no longer be part of Aequus’ management team. “We would like to thank Christina for her substantial contributions and dedication during her time at Aequus, particularly for instilling a fiscal discipline that leaves us well positioned for the future,” said Mr. Janzen. “We wish Christina all the best in her future endeavours.”

Aequus is also pleased to announce it has granted incentive stock options to a consultant and officer of the Company for the right to purchase up to an aggregate of 150,000 common shares of the Company. These stock options are exercisable at a price of $0.34 per share, for a term of eight years, and vest in tranches over a 3 year period. The terms of the stock options granted on July 22, 2016 are in accordance with the Company’s Stock Option Plan.

About Aequus Pharmaceuticals

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) is a Vancouver-based, specialty pharmaceutical company primarily focused on developing and commercializing high quality, differentiated products. Aequus’ development stage pipeline includes several products in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. Aequus intends to commercialize its internal programs in Canada and to establish strategic partnerships to accelerate product development and maximize the reach of its product candidates worldwide. Aequus also has a Canadian commercial platform to build on for the launch of products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information, please visit

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward- looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements include but are not limited to statements relating to: the implementation of our business model and strategic plans; revenue growth trends into the future; expected timing for product launches; the Company’s expected revenues; the regulatory approval of its products; the Company’s ability to attract international partners; and ongoing discussions with and the Company’s ability to secure potential partners to further grow our product portfolio. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining regulatory approvals; general business and economic conditions; the Company’s ability to successfully out license or sell its current products and in-license and develop new products; the assumption that the Company’s current good relationships with third parties will be maintained; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and technology offered by the Company’s competitors; the impact of the coronavirus (COVID-19) on the Company’s operations; and the Company’s ability to protect patents and proprietary rights. In evaluating forward looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading “Risk Factors” in the Company’s Annual Information Form dated April 30, 2021, a copy of which is available on Aequus’ profile on the SEDAR website at, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward looking statements.
Aequus Contact Information